A brief correspondence published in the New England Journal of Medicine has drawn attention to an unusual molecular variant of infantile fibrosarcoma — one driven by a TFG::MET gene fusion — that showed a response to the targeted agent crizotinib.
Background on Infantile Fibrosarcoma
Infantile fibrosarcoma is a rare soft-tissue malignancy that arises predominantly in young children. The condition is most commonly associated with a specific chromosomal rearrangement producing an ETV6::NTRK3 fusion, which has guided the development of NTRK-targeted therapies in recent years. Cases that harbour alternative gene fusions are comparatively uncommon, and their optimal management has been less clearly defined.
A Distinct Molecular Driver
The case described in the NEJM — appearing in Volume 394, Issue 24 — centres on a tumour in which molecular profiling identified a TFG::MET fusion rather than the more typical NTRK3 rearrangement. The MET gene encodes a receptor tyrosine kinase involved in cell growth and proliferation, and fusions involving this gene have been documented across several cancer types, though their appearance in infantile fibrosarcoma appears to be rare.
Crizotinib, a small-molecule inhibitor originally developed to target ALK rearrangements in lung cancer, also carries activity against MET and ROS1 alterations. Its use in this paediatric case reflects a broader trend toward molecularly guided treatment selection in rare childhood tumours.
Potential Significance
According to the report in the New England Journal of Medicine, the infantile fibrosarcoma harbouring the TFG::MET fusion responded to crizotinib treatment. The correspondence spans two pages, consistent with a case report or clinical letter format rather than a large prospective study, meaning the findings are necessarily limited in scope.
Nonetheless, the case adds to a growing body of evidence suggesting that comprehensive molecular profiling of rare paediatric tumours may reveal actionable alterations beyond the most commonly tested fusions. When a tumour's driver is identified at the gene-fusion level, existing inhibitors developed for other cancer types may offer a potential therapeutic avenue.
Limitations and Context
Single case reports carry inherent limitations. Conclusions about efficacy, durability of response, or broader applicability cannot be drawn from one documented instance. Larger case series or prospective studies would be required to establish whether crizotinib represents a reproducible option for MET fusion-positive infantile fibrosarcoma.
The report, published in the journal's June 2026 issue, contributes to the scientific literature on fusion-driven paediatric sarcomas at a time when next-generation sequencing is increasingly used to characterise tumours that do not fit standard molecular profiles.